One capsule, once a day, from the start with minimal pre-initiation requirements1

ZEPOSIA 7-DAY
TITRATION SCHEDULE1
ZEPOSIA® 7 day titration schedule graphic ZEPOSIA® 7 day titration schedule graphic

An up-titration schedule
should be used to reach the
maintenance dose,
as a transient
decrease in heart rate and AV
conduction delays may occur.1

ZEPOSIA may be taken with or without food1
Full Prescribing Information
for ZEPOSIA Has
Graphic highlighting that ZEPOSIA® prescribing information has no genetic testing
NO Genetic Testing
Graphic highlighting that ZEPOSIA® prescribing information has no ophthalmic testing for most patients
NO Ophthalmic Testing for Most Patients1a
Graphic highlighting that ZEPOSIA® prescribing information has no first-dose observation required
NO First-Dose Observation Required
Minimal Pre-Initiation Requirements
Before Initiating Treatment With ZEPOSIA...
  • Obtain a CBC (within 6 months or after discontinuation of prior MS therapy), including lymphocyte count
  • Obtain an ECG to determine whether preexisting conduction abnormalities are present
  • Obtain transaminase and bilirubin levels (within 6 months)
  • Evaluate current and prior medications1
  • Patients without a confirmed history of VZV or without documented VZV vaccination should be tested for antibodies. If VZV or other live attenuated immunizations are required, administer at least 1 month prior to initiation1
aDiabetes mellitus and uveitis increase the risk of macular edema; patients with a history of these conditions should have an ophthalmic evaluation of the fundus, including the macula, prior to treatment initiation. A prompt ophthalmic evaluation is recommended if there is any change in vision while taking ZEPOSIA.1
AV=atrioventricular; CBC=complete blood count; ECG=electrocardiogram; VZV=varicella-zoster virus
ZEPOSIA® Medication bottle
Dosing Considerations
ZEPOSIA® Medication bottle
  • Single maintenance dose of 0.92 mg for all patients
  • If a dose is missed within the first 2 weeks of treatment, reinitiate treatment using the dosing regimen
  • If a dose is missed after the first 2 weeks of treatment, continue with the treatment as planned
  • The mean (CV%) plasma half-life (t1/2) of ZEPOSIA was approximately 21 hours (15%).1
  • The mean (CV%) effective half-life (t1/2) of the active metabolite CC112273 was approximately 11 days.1
Get your patients
started on ZEPOSIA
PATIENT
START FORM
Enroll your patients in ZEPOSIA 360 Support
and help them get started on treatment.
GETTING STARTED VIDEO
Helpful instructions to guide you through the process of getting your patients started on ZEPOSIA.

This website is best viewed
using the horizontal display on
your tablet device.

This website is best viewed
using the vertical display on
your mobile device.